Table 2.

Outcomes of uncontrolled studies evaluating role of aromatase inhibitors in hypogonadism related to obesity and ageing

Study details	Number and nature of patients in the study	AI studied; study duration	Baseline hormone parameters	End of study hormone parameters
De Boer et al.[12]	10 obese men; age 48.2 ± 2.3 years; BMI 42.1 ± 2.6 kg/m2	Lz (7.5 to 17.5 mg per week); 6 weeks	TT: 7.5 ± 1.0 nmol/l E2: 120 ± 20 pmol/l LH: 4.5 ± 0.8 U/l	TT: 23.8 ± 3.0 nmol/l E2: 70 ± 9 pmol/l LH: 14.8 ± 2.3 U/l
Loves et al.[13]	12 obese men; age 48.4 ± 3.3 years; BMI 45.7 ± 3.0 kg/m2	Lz 2.5 mg weekly; 6 months	TT: 5.9 ± 0.5 nmol/l E2: 117.47 ± 15 pmol/l LH: 4.4 ± 0.6 U/l	TT: 19.6 ± 1.4 nmol/l E2: 58.3 ± 9.1 pmol/l LH: 11.1 ± 1.5 U/l
Shah et al.[14]	30 overweight men; age 34 ± 3.1 years; BMI: 28.7 ± 3.5 kg/m2	Anz 1 mg daily; 5 months	TT: 9.39 ± 2.3 nmol/l E2: 123 ± 11 pmol/l LH: 3.4 ± 1.1 U/l Sperm conc.:7.8 mill/ml	TT: 14.29 ± 3.92 nmol/l E2: 58 ± 7 pmol/l LH: 5.4 ± 2.1 U/l Sperm conc.:14.2 mill/mL

AI: aromatase inhibitor; Anz: Anastrozole; BMI: body mass index; conc: concentration; mill: million; Lz: letrozole; TT: total testosterone; E2: estradiol; LH: luteinizing hormone